« Previous
Next »
European Journal of Surgical Oncology
Volume 35, Issue 2
, Pages 151-155
, February 2009
Improvements in breast cancer survival over time, related to adjuvant treatment and node status
References
- . UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet. 2000;355(9217):1822
- . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717
- . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–2106
- . Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst. 2002;94:1626–1634
- . Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901–906
- . Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. Clin Breast Cancer. 2001;2(2):138–143
- The international (Ludwig) breast cancer study group trials I–IV: 15 years follow-up. Ann Oncol. 1994;5(8):717–724
- Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658–1667
- A risk index for early node-negative breast cancer. Br J Surg. 2006;93(5):564–571
- . Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10
mm or less detected clinically and by screening. Eur J Surg. 1994;160(5):271–276 - Ann Surg. 2002;235(6):859–862
- Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93(2):112–120
- Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet. 2004;364(9437):858–868
- . A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol. 1989;7(3):355–366
- . Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol. 1995;13(5):1144–1151
- . Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol. 2004;22(9):1630–1637
- Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9(3):923–930
- . Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol. 1993;11(11):2090–2100
PII: S0748-7983(08)00080-2
doi: 10.1016/j.ejso.2008.02.010
© 2008 Elsevier Ltd. All rights reserved.
« Previous
Next »
European Journal of Surgical Oncology
Volume 35, Issue 2
, Pages 151-155
, February 2009
